Literature DB >> 8324419

Thiazides and seasonal bone change in healthy postmenopausal women.

B Dawson-Hughes1, S Harris.   

Abstract

Thiazide diuretic use has been associated with reduced rates of bone loss and bone density has been found to fluctuate with time of year. Here we examine associations between thiazide use, calcium regulating hormones, and the pattern of bone change during the 6-month intervals of summer/fall when bone density increases and winter/spring when bone density declines. Of the 246 postmenopausal women who completed a 1-year calcium and vitamin D supplement trial, 25 used a thiazide diuretic. In the winter/spring, bone loss was reduced in the thiazide users (for L2-4: 0.46 +/- 0.59 (SE)% for thiazide users vs. -1.02 +/- 0.17% for non-users, P = 0.017; for whole-body: -0.13 +/- 0.25% vs. -0.67 +/- 0.08, P = 0.043). The benefit at the whole body was dose related. Increases in bone density were similar in the two groups in the summer/fall. Associations between thiazide use and net spinal change and between thiazide dose and net whole-body bone change were positive. Thiazide users had lower serum levels of PTH (26.2 +/- 7.6 (SD) ng/l vs. 31.0 +/- 11.7 ng/l, P = 0.009) and 1,25-dihydroxyvitamin D (60.8 +/- 16.2 pmol/l vs. 77.0 +/- 18.7 pmol/l, P < 0.001) in the winter/spring and, in the subset measured, reduced levels of osteocalcin year round (summer/fall: 2.89 +/- 0.82 micrograms/l, n = 10, vs. 3.65 +/- 1.02, n = 82, P = 0.019; winter/spring: 2.54 +/- 0.80 micrograms/l vs. 3.47 +/- 1.07 micrograms/l, P = 0.005). Sodium excretion in the two groups did not differ in the winter/spring. In conclusion, beneficial bone effects of thiazide diuretics occur in the winter/spring and they may result from a decrease in PTH-stimulated bone resorption and an associated reduction in the bone turnover rate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324419     DOI: 10.1016/s0169-6009(08)80119-5

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  7 in total

1.  Mitogenic action of hydrochlorothiazide on human osteoblasts in vitro: requirement for platelet-derived growth factor.

Authors:  K H Lau; X D Song; M Ochi; J E Wergedal
Journal:  Calcif Tissue Int       Date:  1996-12       Impact factor: 4.333

2.  Diuretic use and bone mineral density in older USA men: the osteoporotic fractures in men (MrOS) study.

Authors:  Lionel S Lim; Howard A Fink; Michael A Kuskowski; Jane A Cauley; Kristine E Ensrud
Journal:  Age Ageing       Date:  2005-09       Impact factor: 10.668

Review 3.  Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

Authors:  Khashayar Sakhaee; Naim M Maalouf; Rajiv Kumar; Andreas Pasch; Orson W Moe
Journal:  Kidney Int       Date:  2010-12-01       Impact factor: 10.612

4.  Bone mass, body weight, and seasonal bone changes.

Authors:  H Rico; M Revilla
Journal:  Calcif Tissue Int       Date:  1994-06       Impact factor: 4.333

5.  Influence of weight and seasonal changes on radiogrammetry and bone densitometry.

Authors:  H Rico; M Revilla; J L Cardenas; L F Villa; E Fraile; F J Martín; I Arribas
Journal:  Calcif Tissue Int       Date:  1994-05       Impact factor: 4.333

Review 6.  The association between drugs frequently used by the elderly and vitamin D blood levels: a review of observational and experimental studies.

Authors:  Anne Claire B van Orten-Luiten; André Janse; Rosalie A M Dhonukshe-Rutten; Renger F Witkamp
Journal:  Drugs Aging       Date:  2014-02       Impact factor: 3.923

7.  Hydrochlorothiazide inhibits osteoclastic bone resorption in vitro.

Authors:  T J Hall; M Schaueblin
Journal:  Calcif Tissue Int       Date:  1994-10       Impact factor: 4.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.